377 related articles for article (PubMed ID: 28289078)
1. Delivery is key: lessons learnt from developing splice-switching antisense therapies.
Godfrey C; Desviat LR; Smedsrød B; Piétri-Rouxel F; Denti MA; Disterer P; Lorain S; Nogales-Gadea G; Sardone V; Anwar R; El Andaloussi S; Lehto T; Khoo B; Brolin C; van Roon-Mom WM; Goyenvalle A; Aartsma-Rus A; Arechavala-Gomeza V
EMBO Mol Med; 2017 May; 9(5):545-557. PubMed ID: 28289078
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
3. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
Arora V; Devi GR; Iversen PL
Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
[TBL] [Abstract][Full Text] [Related]
4. Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.
Pérez B; Vilageliu L; Grinberg D; Desviat LR
Nucleic Acid Ther; 2014 Feb; 24(1):48-56. PubMed ID: 24506780
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.
Du L; Gatti RA
J Immunol Methods; 2011 Feb; 365(1-2):1-7. PubMed ID: 21147113
[TBL] [Abstract][Full Text] [Related]
7. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
8. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
10. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
[TBL] [Abstract][Full Text] [Related]
12. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
[TBL] [Abstract][Full Text] [Related]
13. Antisense-based cancer therapeutics: are we there yet?
Rayburn ER; Wang H; Zhang R
Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705
[TBL] [Abstract][Full Text] [Related]
14. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Levin AA
Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
[No Abstract] [Full Text] [Related]
15. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
Isidoro-García M; Dávila I
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
[TBL] [Abstract][Full Text] [Related]
17. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Hammond SM; Abendroth F; Gait MJ; Wood MJA
Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
[TBL] [Abstract][Full Text] [Related]
19. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide treatments for psoriasis.
White PJ; Atley LM; Wraight CJ
Expert Opin Biol Ther; 2004 Jan; 4(1):75-81. PubMed ID: 14680470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]